All terms
Point-of-Care Diagnostics
Diagnostic tests performed near the patient, outside a central lab.
Reviewed by Christian Espinosa, Founder, Blue Goat CyberLast reviewed May 5, 2026
Definition
Point-of-care testing includes lateral-flow rapid tests, handheld blood analyzers (i-STAT), portable molecular platforms (Cepheid GeneXpert, BioFire), and at-home tests. Designed for short turnaround and minimal training. Point-of-care tests run near the patient, such as in clinics, pharmacies or homes, and give fast results. Many seek CLIA waiver so they can be used outside traditional labs. Ease of use, accuracy in untrained hands and connectivity to records are key design factors. What the regulation says
Point-of-care diagnostics are subject to the same regulatory oversight as laboratory-based diagnostics, including requirements for design controls, risk management, and quality system regulation as outlined in 21 CFR Part 820 for the FDA, or Annex I of the EU MDR for devices marketed in Europe. Specific considerations arise due to the diverse intended users and use environments, which influence performance claims and labeling requirements, as detailed in FDA guidance documents on Point-of-Care devices.What this means in practice
CLIA-waived status unlocks the largest commercial markets (physician offices, urgent care, retail pharmacy, OTC). Reimbursement via CPT 87xxx codes with site-of-service modifiers.Examples
- A manufacturer designs a handheld immunoassay device for influenza detection, intended for use in urgent care clinics by nurses, requiring human factors validation to ensure accurate operation with minimal training.
- A company develops a portable molecular diagnostic system for infectious diseases, seeking CLIA waiver to enable its adoption in retail pharmacies for rapid patient screening.
- A startup innovates an at-home blood glucose monitoring system, necessitating extensive usability testing and clear instructional labeling to comply with regulatory expectations for lay user operation.
Common pitfalls
- •A common pitfall is underestimating the human factors engineering challenges associated with diverse user populations and uncontrolled use environments.
- •Failing to adequately validate performance characteristics, such as accuracy and precision, in the actual point-of-care setting can lead to significant regulatory issues.
- •Misinterpreting CLIA waiver requirements or failing to secure the appropriate CLIA status can severely limit market access and legal distribution.
- •Inadequate cybersecurity measures for connected point-of-care devices can pose significant risks to patient data and device functionality, leading to non-compliance with FDA pre-market and post-market cybersecurity guidance.
- •Not addressing shelf-life stability and environmental tolerances for storage and transport, which are often more varied in point-of-care settings, is a common oversight.
Frequently asked questions
Regulatory bodies like the FDA consider Point-of-Care Diagnostics as devices intended for use outside a conventional laboratory setting, often by individuals with minimal training, to provide rapid diagnostic results. The definition emphasizes accessibility and immediacy of results for patient management.
Related terms
Grouped by themeEditor's picks
· Hand-selected related conceptsMore in Market Segments
· Same categoryMarket Segments
Aesthetic & Energy-Based Devices
Lasers, RF, ultrasound, cryolipolysis, and IPL systems used for medical and cosmetic indications, body contouring, hair removal, skin tightening, vascular lesions.
Market Segments
AI Imaging Software
Software that analyzes medical images to triage, detect, or quantify disease.
Market Segments
Cardiac Rhythm Management(CRM)
Implantable and external devices that monitor and treat cardiac arrhythmias, pacemakers, ICDs, CRT devices, and insertable cardiac monitors.
Market Segments
Cardiovascular Devices
Devices for diagnosing, monitoring, or treating cardiovascular disease.
Cited by
Where this term appears across MedTech Terms.
Ecosystems (1)
Sources
4 sourcesSources support the definition or relevant regulatory context, not necessarily every claim on this page. Each is graded against our source-tier hierarchy so you can see what rests on binding law versus commentary.
Tier 2Regulator guidance and consensus· 1Tier 4Trade press and expert commentary· 3
Link health: 4 verified· last checked 2026-06-20· added official documents checked 2026-11-01
AACC·1MedTech Dive·1AdvaMed·1U.S. Food and Drug Administration (FDA)·1
- 1AACC POCTier 4 VerifiedAACCaacc.org
- 2MedTech DiveTier 4 VerifiedMedTech Divemedtechdive.com
- 3AdvaMed - Industry ReportsTier 4 VerifiedAdvaMedadvamed.org
- 4Point-of-care diagnosticsTier 2 VerifiedU.S. Food and Drug Administration (FDA)fda.gov
Inline markers like [1] jump to the matching reference above.